^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    2ms
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    2ms
    A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer (clinicaltrials.gov)
    P3, N=570, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • MSI-H/dMMR • HER-2 negative • CLDN18.2 positive
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • ASP2138
    2ms
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Mayo Clinic | Trial completion date: Apr 2030 --> Jun 2029 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    2ms
    FGFR2b in Gastric Cancer: Translating a Therapeutic Target into a Reliable Biomarker. (PubMed, Cancers (Basel))
    As FGFR2b-directed strategies move forward, their success will depend not only on drug efficacy, but also on standardized testing, careful reporting, and selective reassessment when disease biology changes. FGFR2b therefore offers a useful model for how protein biomarkers can be developed in gastric cancer: not as isolated positive-or-negative labels, but as clinically interpreted variables within a changing therapeutic landscape.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)
    2ms
    Integrated Assessment of Skeletal Muscle Quantity and Quality Is Associated with Survival in Patients with Oesophagogastric Malignancies: A Retrospective Cohort Study. (PubMed, Cancers (Basel))
    Muscle quantity and quality represent complementary dimensions of cancer-associated muscle impairment in oesophagogastric cancer. Collectively, these results suggest that a continuous measure integrating both muscle quantity and muscle quality provides a more clinically informative assessment of muscle impairment than traditional binary definitions of myopenia and myosteatosis.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    2ms
    OESOFIT: Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Masaryk Memorial Cancer Institute
    New trial
    2ms
    Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes. (PubMed, Curr Oncol)
    Bavituximab plus pembrolizumab was well tolerated but showed modest activity, with greater benefit in biomarker-defined subgroups, supporting the biomarker-driven development of tumour microenvironment-targeting combinations in advanced gastric/GOJ adenocarcinomas. NCT04099641.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    Xerna TME™ Panel
    |
    Keytruda (pembrolizumab) • Tarvacin (bavituximab)
    2ms
    Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, West China Second University Hospital
    New trial
    2ms
    Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, West China Second University Hospital
    New trial
    2ms
    Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice (clinicaltrials.gov)
    P=N/A, N=726, Active, not recruiting, Bristol-Myers Squibb
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab)
    2ms
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date • Circulating tumor DNA
    2ms
    Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease (clinicaltrials.gov)
    P1, N=64, Recruiting, Washington University School of Medicine | N=32 --> 64 | Trial completion date: Mar 2033 --> Jun 2034 | Trial primary completion date: Oct 2028 --> Jan 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Hiltonol (poly-ICLC)